For instance, it has been shown that anti-diabetic drugs counteracting insulin resistance (i.e. metformin) seem to decrease PDAC risk, whereas the ones aimed to circulating insulin enhancement (i.e. insulin analogs) manifest an increased risk [36–39]. Here, INS is linked to Insulin resistance.